Overview of Radiation Therapy for Treating Rectal Cancer
Open Access
- 1 January 2014
- journal article
- review article
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 30 (4), 165-174
- https://doi.org/10.3393/ac.2014.30.4.165
Abstract
A major outcome of importance for rectal cancer is local control. Parallel to improvements in surgical technique, adjuvant therapy regimens have been tested in clinical trials in an effort to reduce the local recurrence rate. Nowadays, the local recurrence rate has been reduced because of both good surgical techniques and the addition of radiotherapy. Based on recent reports in the literature, preoperative chemoradiotherapy is now considered the standard of care for patients with stages II and III rectal cancer. Also, short-course radiotherapy appears to provide effective local control and the same overall survival as more long-course chemoradiotherapy schedules and, therefore, may be an appropriate choice in some situations. Capecitabine is an acceptable alternative to infusion fluorouracil in those patients who are able to manage the responsibilities inherent in self-administered, oral chemotherapy. However, concurrent administration of oxaliplatin and radiotherapy is not recommended at this time. Radiation therapy has long been considered an important adjunct in the treatment of rectal cancer. Although no prospective data exist for several issues, we hope that in the near future, patients with rectal cancer can be treated by using the best combination of surgery, radiation therapy, and chemotherapy in near future.Keywords
This publication has 78 references indexed in Scilit:
- Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal CancerJournal of Clinical Oncology, 2012
- Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal CancerJournal of Clinical Oncology, 2012
- Magnetic Resonance Imaging-Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes: MERCURY ExperienceJournal of Clinical Oncology, 2011
- Is the 1-cm Rule of Distal Bowel Resection Margin in Rectal Cancer Based on Clinical Evidence? A Systematic ReviewAnnals of Surgical Oncology, 2011
- Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III TrialJournal of Clinical Oncology, 2011
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME StudyJournal of Clinical Oncology, 2010
- Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal CancerAnnals of Surgical Oncology, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trialThe Lancet, 2009
- Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer SocietyBMC Cancer, 2009